|
|
Volumn 6, Issue 10, 2007, Pages 777-778
|
|
Non-insulin therapies for type 2 diabetes
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALBUGON;
ALOGLIPTIN;
ALPHA GLUCOSIDASE INHIBITOR;
ANTIDIABETIC AGENT;
AVE 0010;
AVE 2268;
CJC 1134PC;
DAPAGLIFLOZIN;
DIPEPTIDYL PEPTIDASE IV INHIBITOR;
EXENDIN 4;
GLITAZONE DERIVATIVE;
GLUCAGON LIKE PEPTIDE 1 DERIVATIVE;
HEMOGLOBIN A1C;
INCB 13739;
LIRAGLUTIDE;
METFORMIN;
ORAL ANTIDIABETIC AGENT;
PIOGLITAZONE;
PLX 204;
PPM 204;
PSN 9301;
R 1439;
R 1440;
R 1583;
ROSIGLITAZONE;
SAXAGLIPTIN;
SITAGLIPTIN;
SULFONYLUREA DERIVATIVE;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
VILDAGLIPTIN;
ARTICLE;
CLINICAL TRIAL;
DRUG BIOAVAILABILITY;
DRUG CONTRAINDICATION;
DRUG DOSAGE FORM COMPARISON;
DRUG EFFICACY;
DRUG FORMULATION;
DRUG HALF LIFE;
DRUG MARKETING;
DRUG MECHANISM;
DRUG RESEARCH;
DRUG SAFETY;
DRUG TOLERABILITY;
EDEMA;
GASTROINTESTINAL TOXICITY;
GLYCEMIC CONTROL;
HEMOGLOBIN BLOOD LEVEL;
HUMAN;
HYPOGLYCEMIA;
MONOTHERAPY;
NAUSEA AND VOMITING;
NON INSULIN DEPENDENT DIABETES MELLITUS;
NONHUMAN;
PRIORITY JOURNAL;
RISK BENEFIT ANALYSIS;
SIDE EFFECT;
SKIN TOXICITY;
UNSPECIFIED SIDE EFFECT;
WEIGHT GAIN;
|
|
EID: 34848892188
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd2420 Document Type: Article |
|
Times cited : (32)
|
|
References (4)
|
